Next week, 6,000 HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
The HIV-resistant gene mutation CCR5 delta 32 has an interesting past. Could it also be the future of HIV treatment and prevention?
Phase 3 Results With Dual Therapy Cabotegravir/Rilpivirine Long-Acting Injections: ATLAS and FLAIR Studies
Two oral presentations at CROI 2019 showed that dual therapy with long-acting monthly injections resulted in very low levels of virological failure with high participant preference for injections compared to oral combinations.
Richard Jefferys, an expert in HIV cure research, spoke to TheBodyPro about this new case of HIV remission -- and the danger in rushing to publish these stories, especially for people who live with stigma.
UK Patient Likely to Be the Second Person Cured of HIV: Two Further Cases at CROI 2019 of HIV Remission After Allogenic Stem Cell Transplants
The procedure used in this case was similar to that used in the only previously confirmed HIV cure case, "Berlin patient" Timothy Ray Brown, albeit with a somewhat less aggressive approach.
Results from a proof-of-principle study in macaques showing that treatment with broadly neutralising antibodies might play a role in key stages for an HIV cure.
No HIV Evolution in Plasma or Lymph Nodes on Suppressive ART and No Impact From Further Intensification
Two studies presented at CROI 2018 support the idea that ART reaches everywhere in the body that it needs to, and that residual ongoing HIV replication comes from HIV infected cells that were archived before ART was started.
The experimental drug ibalizumab, a monoclonal antibody, continues to effectively lower viral load in people with drug-resistant HIV through 48 weeks of treatment, as potential FDA approval nears.
A single-tablet combination D/C/F/TAF proved virologically noninferior to continuing a suppressive boosted protease inhibitor plus F/TDF at 48 weeks in the phase 3 randomized Emerald trial.
Two oral presentations and numerous posters at the 16th European AIDS Conference included new data on using dolutegravir-based dual ART (many with 3TC) as a switch option for people currently on stable three-drug ART.